Compare LEGN & XP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LEGN | XP |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 10.1B |
| IPO Year | 2020 | 2019 |
| Metric | LEGN | XP |
|---|---|---|
| Price | $19.07 | $18.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | ★ $63.08 | $22.67 |
| AVG Volume (30 Days) | 1.7M | ★ 6.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 0.90% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $46.27 | $19.15 |
| Revenue Next Year | $28.77 | $13.67 |
| P/E Ratio | ★ N/A | $11.42 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.24 | $12.20 |
| 52 Week High | $45.30 | $23.13 |
| Indicator | LEGN | XP |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 40.23 |
| Support Level | $17.46 | $18.05 |
| Resistance Level | $23.68 | $20.37 |
| Average True Range (ATR) | 0.95 | 1.00 |
| MACD | 0.22 | -0.36 |
| Stochastic Oscillator | 41.87 | 2.55 |
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.